Spectral AI (MDAI) released an investor presentation outlining its commercial launch strategy for the DeepView® System, its AI-powered device for wound healing prediction. The presentation follows the company's receipt of FDA De Novo classification, authorizing U.S. commercial sales, and details the go-to-market plan supported by a significant government contract.
Key Details
- Regulatory Milestone: The company received FDA De Novo classification for its DeepView® System on May 21, 2026, for predicting burn wound healing potential.
- Commercial Outlook: First commercial sales are targeted by the end of 2026. An initial deployment of up to 30 DeepView® systems to U.S. burn and trauma centers will be subsidized under a contract with BARDA (Biomedical Advanced Research and Development Authority).
- Business Model: The commercial model includes revenue from both device placements (capital purchase or lease) and recurring, multi-year software-as-a-service (SaaS) contracts for each unit.